Efficacy and safty of tenofovir alafenamide treatment swithed from entecavir in patinets with chronic hepatitis B.
Not Applicable
- Conditions
- Chronic hepatitis B
- Registration Number
- JPRN-UMIN000031754
- Lead Sponsor
- Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital Toranomon Hospital Kajigaya Department of Hepatology
- Brief Summary
This clinical trail was discontinued.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
Ccr less than 15 mL/min patients who can't have informed consent. Doctors jugde inadequate patients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The mean and median decline in HBsAg level of tenofovir alafenamide at 1, 2 , 3 years after randomization.
- Secondary Outcome Measures
Name Time Method HBsAg and HBeAg seloclearance rates at 1, 2 , 3 years after randomization. Rates of HBsAg < 100 IU/mL amd < 1000 IU/mL and HBV DNA elevation rates. Ccr, eGFR, Urine and serum phosphorus